This week saw several medtech sector leaders put out their quarterly earnings and performances, and at first glance they look to be solid overall. Among the list of large-cap players listed below (see Table 1), none reported shrinking revenue while net incomes look to have widened comfortably. Boston Scientific, Edwards Lifesciences and Stryker all reported double-digit topline growth for the third quarter, while CR Bard, Philips HealthTech. Teleflex and Thermo Fisher's specialty diagnostics business reported more modest, single-digit increases. However, a deeper dive shows not all is what it seems. These are who we believe to be the real winners and losers:
CR Bard Inc. (BCR) has raised its financial guidance for 2016 again following an encouraging third quarter which saw the company beat analysts' expectations. Q3 sales went up 9%...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?